bioRxivBioinformaticsPreprint
The COVID-19 PHARMACOME: A method for the rational selection of drug repurposing candidates from multimodal knowledge harmonization
Bruce T. SchultziD, Andrea ZalianiiD, Christian EbelingiD, Jeanette ReinshageniD, Denisa BojkováiD, Vanessa Lage‐RupprechtiD, Reagon KarkiiD, Soeren LukasseniD, Yojana GadiyaiD, Neal G. RavindraiD, Sayoni DasiD, Shounak BaksiiD, Daniel Domingo‐FernándéziD, Manuel LentzeniD, Mark A. Strivens, Tamara RaschkaiD, Jindrich Jr. CinatliD, Lauren Nicole DeLongiD, Philip M. GribboniD, Gerd GeißlingeriD, Sandra CiesekiD, David van DijkiD, Steve GardneriD, Alpha Tom KodamulliliD, Holger FröhlichiD, , Martin Hofmann‐ApitiusiD
Abstract
The SARS-CoV-2 pandemic has challenged researchers at a global scale. The scientific communitys massive response has resulted in a flood of experiments, analyses, hypotheses, and publications, especially in the field of drug repurposing. However, many of the proposed therapeutic compounds obtained from SARS-CoV-2 specific assays are not in agreement and thus demonstrate the need for a singular source of COVID-19 related information from which a rational selection of drug repurposing candidates can be made. In this paper, we present the COVID-19 PHARMACOME, a comprehensive drug-target-mechanism graph generated from a compilation of 10 separate disease maps and sources of experimental data focused on SARS-CoV-2 / COVID-19 pathophysiology. By applying our systematic approach, we were able to predict the synergistic effect of specific drug pairs, such as Remdesivir and Thioguanosine or Nelfinavir and Raloxifene, on SARS-CoV-2 infection. Experimental validation of our results demonstrate that our graph can be used to not only explore the involved mechanistic pathways, but also to identify novel combinations of drug repurposing candidates.
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro
T. Bobrowski, L. Chen, … E. N. Muratov·bioRxiv·Jun 29, 2020
- Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic
Sarel Cohen, Moshik Hershcovitch, … Tobias Friedrich·PLoS ONEPeer-reviewed·Mar 16, 2023
- A Workflow of Integrated Resources to Catalyze Network Pharmacology Driven COVID-19 Research
Gergely Zahoránszky-Köhalmi, Vishal B. Siramshetty, … Tudor Ionel Oprea·Journal of Chemical Information and ModelingPeer-reviewed·Jan 20, 2022
- Identification of SARS-CoV-2 induced pathways reveal drug repurposing strategies
N. Han, W. Hwang, … T. Kouzarides·bioRxiv·Aug 24, 2020
- Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2
S. B. Biering, E. Van Dis, … S. A. Stanley·bioRxiv·Dec 30, 2020
- A genetically based computational drug repurposing framework for rapid identification of candidate compounds: application to COVID-19
Georgios Voloudakis, Kyung Min Lee, … Panos Roussos·medRxiv·Jan 10, 2025